90 / 1851
Economics and logistics of personalized
medicine trials
•
Each center needs to open multiple studies to be
economically viable
•
Greater regulatory burden (protocols emendments,
SUSARs)
•
Cost per case increased
•
Limited experience accumulated per centre
•
Collection of trial data by sponsor with sharing of
toxicity data by grade and frequency on a regular
basis throught protocol conduct